Cybin files two new patent applications in support of its proprietary psychedelic compounds.

MindMed announces joining a research consortium, the Patient-Reported Outcome Consortium, to assist in its mission to advance medical innovation.

Nearly half of U.S. adults—49%—have tried cannabis, according to a Gallup poll, which also found 12% of U.S. adults use it regularly.

Mydecine signs a 5-year research agreement with Johns Hopkins University, with an initial focus on smoking cessation.

Optimi Health announces it has filed a Final Shelf Prospectus.

New York-based cannabis firm PharmaCann is planning an initial public offering that could value the company at over $1 billion, according to a Reuters report citing sources familiar with the plan.

Cybin announces the filing of a non-provisional patent application, the company’s 14th patent application.

Nearly one year after the Ann Arbor, Michigan City Council voted to decriminalize a wide-range of psychedelics, lawmakers on Monday approved a resolution to officially designate September as Entheogenic Plants and Fungi Awareness Month.

Field Trip Health Ltd., a leader in the development and delivery of psychedelic therapies, reported its fiscal first quarter 2022 results for the three months ended June 30, 2021.

The THC limit for cannabis edibles in Alaska will be 10 milligrams per serving, doubling the current product limit, starting September 1.